Skip to main content
SpringerLink
Log in

Intersection Between Chronic Kidney Disease and Cardiovascular Disease

  • Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The incidence of chronic kidney disease is increasing worldwide, and the previously decreasing incidence of cardiovascular disease has now plateaued. Understanding the intersection of both heart and kidney disease is crucial.

Recent Findings

Chronic kidney disease and cardiovascular disease share common risk factors and specific pathogenic mechanisms and impact a significant segment of the population. Patients with chronic kidney disease are more likely to have cardiovascular disease than progress to end-stage kidney disease requiring renal replacement therapy.

Summary

We discuss shared risk factors and mechanisms for cardiovascular and chronic kidney disease. The following also addresses contemporary cardiovascular treatment considerations in patients with chronic kidney disease with a focus on atherosclerotic cardiovascular disease and heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cases and observations illustrative of renal disease, accompanied with the secretion of albuminous urine. Med Chir Rev. 1836;25(49):23–35.

  2. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–73. https://doi.org/10.1016/S0140-6736(12)61350-6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–61. https://doi.org/10.1016/S0140-6736(12)61272-0.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49–61. https://doi.org/10.1038/ki.2013.444.

    Article  PubMed  Google Scholar 

  5. Bansal N, Katz R, Robinson-Cohen C, Odden MC, Dalrymple L, Shlipak MG, et al. Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies. JAMA Cardiol. 2017;2(3):314–8. https://doi.org/10.1001/jamacardio.2016.4652.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. https://doi.org/10.1056/NEJMoa041031.

    Article  CAS  PubMed  Google Scholar 

  7. Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81. https://doi.org/10.1016/S0140-6736(10)60674-5.

    Article  Google Scholar 

  8. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. https://doi.org/10.1016/S0140-6736(13)60595-4.

    Article  PubMed  Google Scholar 

  9. Turin TC, Tonelli M, Manns BJ, Ravani P, Ahmed SB, Hemmelgarn BR. Chronic kidney disease and life expectancy. Nephrol Dial Transplant. 2012;27(8):3182–6. https://doi.org/10.1093/ndt/gfs052.

    Article  CAS  PubMed  Google Scholar 

  10. Turin TC, Tonelli M, Manns BJ, Ahmed SB, Ravani P, James M, et al. Proteinuria and life expectancy. Am J Kidney Dis. 2013;61(4):646–8. https://doi.org/10.1053/j.ajkd.2012.11.030.

    Article  PubMed  Google Scholar 

  11. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41(1):47–55. https://doi.org/10.1016/s0735-1097(02)02663-3.

    Article  PubMed  Google Scholar 

  12. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013;15(3):340. https://doi.org/10.1007/s11886-012-0340-4.

    Article  PubMed  Google Scholar 

  13. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e143. https://doi.org/10.1161/CIR.0000000000000625.

    Article  PubMed  Google Scholar 

  14. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation. 2004;109(8):1004–9. https://doi.org/10.1161/01.CIR.0000116764.53225.A9.

    Article  PubMed  Google Scholar 

  15. McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail. 2012;5(3):309–14. https://doi.org/10.1161/CIRCHEARTFAILURE.111.966242.

    Article  PubMed  Google Scholar 

  16. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–30. https://doi.org/10.1016/j.cardfail.2007.03.011.

    Article  PubMed  Google Scholar 

  17. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113(5):671–8. https://doi.org/10.1161/CIRCULATIONAHA.105.580506.

    Article  PubMed  Google Scholar 

  18. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293(14):1737–45. https://doi.org/10.1001/jama.293.14.1737.

    Article  CAS  PubMed  Google Scholar 

  19. Sumida K, Lau WL, Kovesdy CP, Kalantar-Zadeh K, Kalantar-Zadeh K. Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens. 2021;30(1):75–84. https://doi.org/10.1097/MNH.0000000000000661.

    Article  CAS  PubMed  Google Scholar 

  20. Herrema H, Nieuwdorp M, Groen AK. Microbiome and cardiovascular disease. Handb Exp Pharmacol. 2020. https://doi.org/10.1007/164_2020_356.

  21. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115–26. https://doi.org/10.1056/NEJM199901143400207.

    Article  CAS  PubMed  Google Scholar 

  22. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40. https://doi.org/10.1016/S0140-6736(09)61717-7.

    Article  CAS  Google Scholar 

  23. Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012;178:100–5. https://doi.org/10.1159/000337821.

    Article  PubMed  Google Scholar 

  24. Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006;17(4 Suppl 2):S145–7. https://doi.org/10.1681/ASN.2005121320.

    Article  CAS  PubMed  Google Scholar 

  25. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524–38. https://doi.org/10.1046/j.1523-1755.2002.00600.x.

    Article  CAS  PubMed  Google Scholar 

  26. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol. 2004;15(3):538–48. https://doi.org/10.1097/01.asn.0000111744.00916.e6.

    Article  CAS  PubMed  Google Scholar 

  27. Jagadeswaran D, Indhumathi E, Hemamalini AJ, Sivakumar V, Soundararajan P, Jayakumar M. Inflammation and nutritional status assessment by malnutrition inflammation score and its outcome in pre-dialysis chronic kidney disease patients. Clin Nutr. 2019;38(1):341–7. https://doi.org/10.1016/j.clnu.2018.01.001.

    Article  CAS  PubMed  Google Scholar 

  28. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85–97. https://doi.org/10.1161/CIRCULATIONAHA.106.678342.

    Article  PubMed  Google Scholar 

  29. Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64(5):924–8. https://doi.org/10.1161/HYPERTENSIONAHA.114.03575.

    Article  CAS  PubMed  Google Scholar 

  30. Stam F, van Guldener C, Becker A, Dekker JM, Heine RJ, Bouter LM, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol. 2006;17(2):537–45. https://doi.org/10.1681/ASN.2005080834.

    Article  CAS  PubMed  Google Scholar 

  31. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 1999;19(5):1168–72. https://doi.org/10.1161/01.atv.19.5.1168.

    Article  CAS  PubMed  Google Scholar 

  32. Desir GV, Wang L, Peixoto AJ. Human renalase: a review of its biology, function, and implications for hypertension. J Am Soc Hypertens. 2012;6(6):417–26. https://doi.org/10.1016/j.jash.2012.09.002.

    Article  CAS  PubMed  Google Scholar 

  33. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572–5. https://doi.org/10.1016/0140-6736(92)90865-z.

    Article  CAS  PubMed  Google Scholar 

  34. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62(1):339–45. https://doi.org/10.1046/j.1523-1755.2002.00437.x.

    Article  CAS  PubMed  Google Scholar 

  35. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113–7. https://doi.org/10.1016/s0140-6736(01)07217-8.

    Article  CAS  PubMed  Google Scholar 

  36. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27(3):347–54. https://doi.org/10.1016/s0272-6386(96)90357-1.

    Article  CAS  PubMed  Google Scholar 

  37. Shenasa M, Shenasa H, El-Sherif N. Left ventricular hypertrophy and arrhythmogenesis. Card Electrophysiol Clin. 2015;7(2):207–20. https://doi.org/10.1016/j.ccep.2015.03.017.

    Article  PubMed  Google Scholar 

  38. Urena-Torres P, D'Marco L, Raggi P, Garcia-Moll X, Brandenburg V, Mazzaferro S, et al. Valvular heart disease and calcification in CKD: more common than appreciated. Nephrol Dial Transplant. 2020;35(12):2046–53. https://doi.org/10.1093/ndt/gfz133.

    Article  CAS  PubMed  Google Scholar 

  39. Rodin R, Chan CT. Determinants and prevention of coronary disease in patients with chronic kidney disease. Can J Cardiol. 2019;35(9):1181–7. https://doi.org/10.1016/j.cjca.2019.05.025.

    Article  PubMed  Google Scholar 

  40. Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P. Chronic kidney disease and premature ageing. Nat Rev Nephrol. 2014;10(12):732–42. https://doi.org/10.1038/nrneph.2014.185.

    Article  CAS  PubMed  Google Scholar 

  41. Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2017;91(4):808–17. https://doi.org/10.1016/j.kint.2016.09.024.

    Article  PubMed  Google Scholar 

  42. Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610–23. https://doi.org/10.1038/nrneph.2016.113.

    Article  CAS  PubMed  Google Scholar 

  43. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589–96. https://doi.org/10.1016/j.jacc.2008.05.068.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol. 2016;13(1):28–35. https://doi.org/10.1038/nrcardio.2015.134.

    Article  CAS  PubMed  Google Scholar 

  45. Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021–30. https://doi.org/10.1038/sj.ki.5001934.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296(11):1377–84. https://doi.org/10.1001/jama.296.11.1377.

    Article  CAS  PubMed  Google Scholar 

  47. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med. 2016;176(1):121–4. https://doi.org/10.1001/jamainternmed.2015.6102.

    Article  PubMed  Google Scholar 

  48. Zannad F, Rossignol P. Cardiovascular outcome trials in patients with advanced kidney disease: time for action. Circulation. 2017;135(19):1769–71. https://doi.org/10.1161/CIRCULATIONAHA.117.027338.

    Article  PubMed  Google Scholar 

  49. Laffin LJ, Hofmann-Bowman MA. Beyond hypertension and cardio-renal syndrome: the need to acknowledge and incorporate renal disease in cardiac electrophysiology trials. Am J Nephrol. 2018;48(1):32–5. https://doi.org/10.1159/000491024.

    Article  PubMed  Google Scholar 

  50. Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med. 2020;382(17):1608–18. https://doi.org/10.1056/NEJMoa1915925Major dedicated trial to the management of stable coronary artery disease in advanced chronic kidney disease.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382(15):1395–407. https://doi.org/10.1056/NEJMoa1915922.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. Am J Cardiol. 2009;104(12):1647–53. https://doi.org/10.1016/j.amjcard.2009.07.043.

    Article  PubMed  Google Scholar 

  53. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010;121(3):357–65. https://doi.org/10.1161/CIRCULATIONAHA.109.865352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation. 2015;131(12):1123–49. https://doi.org/10.1161/CIR.0000000000000183.

    Article  PubMed  Google Scholar 

  55. de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015;3(3):181–90. https://doi.org/10.1016/S2213-8587(14)70246-3.

    Article  CAS  PubMed  Google Scholar 

  56. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92. https://doi.org/10.1016/S0140-6736(11)60739-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807–17. https://doi.org/10.1093/eurheartj/eht065.

    Article  CAS  PubMed  Google Scholar 

  58. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.

    Article  CAS  PubMed  Google Scholar 

  59. Sharma G, Martin SS, Blumenthal RS. Effects of omega-3 fatty acids on major adverse cardiovascular events: what matters most: the drug, the dose, or the placebo? JAMA. 2020;324(22):2262–4. https://doi.org/10.1001/jama.2020.22387.

    Article  PubMed  Google Scholar 

  60. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29. https://doi.org/10.1056/NEJMoa2025845Pivotal tiral of novel nonsteroidal selective mineralocorticoid receptor antagonist (finerenone) demonstrating its efficacy in reducing progression of CKD and reducing CV risk among patients with type 2 diabetes and CKD.

  61. Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540–52. https://doi.org/10.1161/CIRCULATIONAHA.120.051898.

    Article  CAS  PubMed  Google Scholar 

  62. Bajaj A, Damrauer SM, Anderson AH, Xie D, Budoff MJ, Go AS, et al. Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort). Arterioscler Thromb Vasc Biol. 2017;37(10):1971–8. https://doi.org/10.1161/ATVBAHA.117.309920.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59(4):577–85. https://doi.org/10.1194/jlr.R083626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J. 2020;13(5):753–7. https://doi.org/10.1093/ckj/sfaa001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803. https://doi.org/10.1016/j.jacc.2017.04.025.

    Article  PubMed  Google Scholar 

  66. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. https://doi.org/10.1056/NEJM199909023411001.

    Article  CAS  PubMed  Google Scholar 

  67. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. https://doi.org/10.1056/NEJMoa030207.

    Article  CAS  PubMed  Google Scholar 

  68. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077.

    Article  CAS  PubMed  Google Scholar 

  69. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(3):542–51. https://doi.org/10.2215/CJN.04750908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Hein AM, Scialla JJ, Edmonston D, Cooper LB, DeVore AD, Mentz RJ. Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. JACC Heart Fail. 2019;7(5):371–82. https://doi.org/10.1016/j.jchf.2019.02.009.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Heywood JT, Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol. 2010;105(8):1140–6. https://doi.org/10.1016/j.amjcard.2009.12.016.

    Article  PubMed  Google Scholar 

  72. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6(6):489–98. https://doi.org/10.1016/j.jchf.2018.02.004Subgroup analysis of PARADIGM study assessing the impact on sacubitril-valsartan in HF patients with CKD.

    Article  PubMed  Google Scholar 

  73. American DA. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111–S24. https://doi.org/10.2337/dc21-S009.

    Article  Google Scholar 

  74. de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020;98(4):839–48. https://doi.org/10.1016/j.kint.2020.06.024.

    Article  CAS  PubMed  Google Scholar 

  75. McMurray JJV, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine. Circulation. 2021;143(9):875–7. https://doi.org/10.1161/CIRCULATIONAHA.120.052926.

    Article  PubMed  Google Scholar 

  76. Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021;232:10–22. https://doi.org/10.1016/j.ahj.2020.10.064Contemporary meta-analysis regarding the CV and kidney outcomes in trials of SGLT2 inhibitors.

    Article  CAS  PubMed  Google Scholar 

  77. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–54. https://doi.org/10.1016/S2213-8587(19)30256-6.

    Article  CAS  PubMed  Google Scholar 

  78. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816Trial of dapagliflozin in CKD that was not limited to diabetic kidney disease, demonstrating beneficial kidney and cardiovascular outcomes.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA

    Luke J. Laffin

  2. Am. Heart Assoc. Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Chicago Medicine, 5841 S. Maryland Ave, MC 1027, Chicago, IL, 60637, USA

    George L. Bakris

Authors
  1. Luke J. Laffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George L. Bakris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George L. Bakris.

Ethics declarations

Conflict of Interest

Dr. Laffin reports: Vascular Dynamics—Hypertension Committee member. LucidAct Health—Medical Advisor. Medtronic—Consultant.

Dr. Bakris reports: Bayer, Janssen, Novo Nordisk, Vascular Dynamics-Steering Committee or Principal Investigator of international renal outcome trials with funding going to the University of Chicago Medicine. Consulting fees are from Merck, Relypsa, Vifor, Bayer, Novo Nordisk, Alnylam, Ionis, and KBP Biosciences.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Global Cardiovascular Health

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Laffin, L.J., Bakris, G.L. Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Curr Cardiol Rep 23, 117 (2021). https://doi.org/10.1007/s11886-021-01546-8

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11886-021-01546-8

Keywords

Search

Navigation